Integrin-based therapeutics: biological basis, clinical use and new drugs - Wikidata - awgldk - TriplyDB

Integrin-based therapeutics: biological basis, clinical use and new drugs

Integrin-based therapeutics: biological basis, clinical use and new drugs

http://www.wikidata.org/entity/Q26773026

about

Research advances on structure and biological functions of integrins Neutrophil recruitment limited by high-affinity bent β2 integrin binding ligand in cis.Direct evidence for cell adhesion-mediated radioresistance (CAM-RR) on the level of individual integrin β1 clusters.β1 integrin signaling promotes neuronal migration along vascular scaffolds in the post-stroke brain RGD-Binding Integrins in Head and Neck Cancers.Insights into the Binding of Cyclic RGD Peptidomimetics to α5β1 Integrin by using Live-Cell NMR And Computational Studies.Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44.Dynamin2 controls Rap1 activation and integrin clustering in human T lymphocyte adhesion Integrin αIIbβ3 outside-in signaling.Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.The Present and Future of Inflammatory Bowel Disease Treatment.αvβ3- or α5β1-Integrin-Selective Peptidomimetics for Surface Coating.The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.Immunomodulatory Nanomedicine.Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators Frontiers in Drug Research and Development for Inflammatory Bowel Disease.Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance.Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells.A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins.Targeted-TERS detection of integrin receptors on human cancer cells.Exploring the Role of RGD-Recognizing Integrins in Cancer.Integrins as Therapeutic Targets: Successes and Cancers.Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment.Targeting αv Integrins in Pancreatic Fibrosis: Progress in Resolving the Scar.Integrin beta 1 inhibition alleviates the chronic hyperproliferative dermatitis phenotype of SHARPIN-deficient mice.Paxillin genes and actomyosin contractility regulate myotome morphogenesis in zebrafish.Investigating the Interaction of Cyclic RGD Peptidomimetics with αVβ₆ Integrin by Biochemical and Molecular Docking Studies.Novel c(RGDyK)-based conjugates of POPAM and 5-fluorouracil for integrin-targeted cancer therapy.Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3.In silico analysis of structural modifications in and around the integrin αIIb genu caused by ITGA2B variants in human platelets with emphasis on Glanzmann thrombasthenia.Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases.A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense.Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma.The interplay between extracellular matrix remodelling and kinase signalling in cancer progression and metastasis.ITGA2B and ITGB3 gene mutations associated with Glanzmann thrombasthenia.Herbal compound Teng-Long-Bu-Zhong-Tang inhibits metastasis in human RKO colon carcinoma.Neutrophils in critical illness.ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphat αEβ7, α4β7 and α4β1 integrin contributions to T cell distribution in blood, cervix and rectal tissues: Potential implications for HIV transmission.Dysregulation of chemokine receptor expression and function in leukocytes from ALS patients.

P2860

Q26741077-3D52629B-ED1B-498A-ACDB-00134DF38849 Q27329905-52387242-5D3D-4EA8-B38A-128F892F788C Q33794146-003223D3-9A6B-4B15-AE90-A79940F68835 Q33809470-FAAF4A9A-5F03-493C-BEAF-DF651DFF7041 Q33832735-8AD303B3-9BC0-4AC6-89AA-814E43BA85DB Q36272448-71316555-6642-4043-8F3B-99AC23196904 Q36298393-07DE06A1-9B44-450A-A54D-170EBB8D2962 Q36300709-E393AACA-340E-41D1-99D4-6283231909E3 Q38644725-77EA0EDE-8024-48A3-894A-45A188FD6B35 Q38805575-2C4DB625-5B16-41D3-B641-CB63772E6100 Q38834699-CF5E5E2C-D963-41AD-B508-35C60A2088C5 Q38852942-2617A0DA-3DFF-4E46-950C-EB4CB574A133 Q38950433-C426DA23-DB69-4B13-9C11-38D40AF1F719 Q39224331-66301F6D-8AF2-4BA1-859C-943623EA7798 Q39415173-BE3C5397-6715-4095-B1C7-FDDE2ED36534 Q39424463-A3B5DCF5-E5CE-43FD-BC40-5AF3E1590E0C Q39531973-5B6D1EC7-3BE7-4CDB-84C8-C0450CEE63BB Q40181004-7E9F55FE-4AF8-48D6-8104-BD54186A3C94 Q41195862-1A82E299-D538-4D0E-97A1-09C03A053F8A Q41335542-AB8C9A95-031A-4C3B-BA38-A593B0D4416B Q41670915-8DA15DDF-8D3F-47CD-AE03-3E4A7D61C8A6 Q41670949-38EDCB7A-556E-4CD6-B0FF-63877083B265 Q42353677-B96CE312-37BA-4969-9FFC-7D1ECBCE0D1C Q42389570-C2182CC6-763E-40CF-B327-0A99EB86A96D Q42685208-7AFC6CC0-B75A-46D1-A6FC-2EF63A0050AB Q47073677-B0488C4A-DFC8-48BC-8A5F-8BA8ABEAAD6D Q47107605-D13E0283-4A79-4AD1-81BE-8F289B29FC43 Q47432742-1CB46409-22FD-41D6-B289-E4E1D4F54733 Q47600958-545B5829-BDAA-4613-8BC2-95459143B7D9 Q47802960-2673C3A4-0F0F-4654-A54A-6F82BF8B66C0 Q47881730-863C682B-81CD-463A-BC3E-DF8AB19F3C7D Q48095930-FFE45E1C-F6BD-40A9-88F9-2124826CD5AC Q48151426-68C4C64B-1CBF-4F25-BD49-33AC40F6F488 Q48247148-3B7E2446-13DA-4978-8E68-1B512C0463A7 Q48326012-9BA89E9A-3596-4889-ABB4-A9EB4344139D Q49205660-D0C1B5EB-AC1E-4A47-86CD-FFBA79B85403 Q49788597-ECB99EA2-5D95-40A3-BB6E-76518D21DB57 Q50086043-4381AB72-1045-4789-9B23-CDF0C11E0311 Q50114397-39B337A3-CE98-4CFC-B9EF-640082D46D45 Q51758743-66598666-C45D-4B3F-B7CA-45F82DAC42C4

P2860

Integrin-based therapeutics: biological basis, clinical use and new drugs

http://www.wikidata.org/entity/Q26773026

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Integrin-based therapeutics: biological basis, clinical use and new drugs

@ast

Integrin-based therapeutics: biological basis, clinical use and new drugs

@en

Integrin-based therapeutics: biological basis, clinical use and new drugs

@nl

type

label

Integrin-based therapeutics: biological basis, clinical use and new drugs

@ast

Integrin-based therapeutics: biological basis, clinical use and new drugs

@en

Integrin-based therapeutics: biological basis, clinical use and new drugs

@nl

prefLabel

Integrin-based therapeutics: biological basis, clinical use and new drugs

@ast

Integrin-based therapeutics: biological basis, clinical use and new drugs

@en

Integrin-based therapeutics: biological basis, clinical use and new drugs

@nl

P1433

Q26773026-D9BD6455-21A1-4683-B1F3-F01F3B9BCB59

P1476

Q26773026-24A33DE7-4D68-463D-B5F3-DA003186A7B0

P2093

Q26773026-6F9F8890-7075-4F17-89A5-645F624F9727

Q26773026-A98CE9B4-7493-4684-82B5-E51992E9A5C5

Q26773026-DAAE6F22-45B3-4F96-B64C-934C7AB40BD1

Q26773026-FDD84D9A-5874-4AB8-B7E3-4D5F24A55D1B

P2860

Q26773026-047DD8A9-0680-4055-ADBA-8FA168AD7276

Q26773026-051621E8-BA09-4BF1-9358-546678AA4C39

Q26773026-0A22C004-CCE3-443D-A9D0-FD243A66C857

Q26773026-0A5423FA-0E5B-4B1D-8E97-67F90CEB14E2

Q26773026-0E0FBE1B-6638-47CC-BB8E-255A4B309663

Q26773026-0FB22BE0-8F8B-4534-B502-27571962FDE9

Q26773026-12B97416-12C0-4E0E-A4F1-96A0A09AC083

Q26773026-171E1A8C-8492-4D5B-9B36-076DA435359D

Q26773026-186B2FB4-C354-4CDA-9BE4-6AEC8F8BB1BD

Q26773026-18BAB201-E40D-4D26-9061-F6B2E906BC1C

P2888

Q26773026-5C4A23EB-525D-414E-AF40-DD71B210A5C1

P304

Q26773026-0900B28C-DC65-40EF-9D45-A4E5C5F65B03

P31

Q26773026-CE4ACDA6-E7CA-48B3-BEE3-0ADF2BD9280C

P3181

Q26773026-F017707A-A8F5-497B-AD64-93BD0D658390

P356

Q26773026-42236AC1-108A-4C43-A42D-6922DA1243CE

P407

Q26773026-8D7FC74A-3ED9-4A0B-A814-9602B8E1A482

P433

Q26773026-FF92283E-9498-4DC2-8633-70D8EB984112

P478

Q26773026-A7FDC747-BE0C-4E2C-BA63-E10C0E7B6EC4

P577

Q26773026-1397C747-7567-4CE3-80E7-8FFAA89BC35E

P6179

Q26773026-7D80D16B-647B-4F32-A7DD-3350B16D8E6A

P698

Q26773026-EE3A5767-73B2-44A9-8837-56D7A950481B

P932

Q26773026-B13D8005-A628-470C-90B2-230778B35F8D

P3181

P356

P1433

Nature Reviews Drug Discovery

P1476

Integrin-based therapeutics: biological basis, clinical use and new drugs

@en

P2093

Jesus Rivera-Nieves

http://www.w3.org/2001/XMLSchema#string

Klaus Ley

http://www.w3.org/2001/XMLSchema#string

Sanford Shattil

http://www.w3.org/2001/XMLSchema#string

William J Sandborn

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Src kinase activation by direct interaction with the integrin beta cytoplasmic domain

gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors

MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1

Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease

Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation.

Structure of an integrin with an αI domain, complement receptor type 4

Integrins: bidirectional, allosteric signaling machines

The immunological synapse: a molecular machine controlling T cell activation

Platelet-collagen interaction: is GPVI the central receptor?

P2888

P304

173-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3804756

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NRD.2015.10

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1040308214

http://www.w3.org/2001/XMLSchema#string

P698

26822833

http://www.w3.org/2001/XMLSchema#string

P932

4890615

http://www.w3.org/2001/XMLSchema#string